Out to pi­o­neer gene edit­ing in Chi­na, Edi­Gene bags $67M to be­gin clin­i­cal test­ing for β-tha­lassemia ther­a­py, uni­ver­sal CAR-T

A gene edit­ing play­er hail­ing from Bei­jing has clinched $67 mil­lion to steer two of its lead can­di­dates in­to the clin­ic — and to prove it­self as a CRISPR pi­o­neer in Chi­na.

Edi­Gene gath­ered the Se­ries B from a slate of top-tier Chi­nese in­vestors, in­clud­ing 3H Health In­vest­ment (who led the round), Se­quoia Cap­i­tal Chi­na, Al­win Cap­i­tal and Kun­lun Cap­i­tal. Pre­vi­ous back­ers, in­clud­ing IDG Cap­i­tal, Lil­ly Asia Ven­ture, Hua­gai Cap­i­tal and Green Pine Cap­i­tal Part­ners, al­so par­tic­i­pat­ed.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN